Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Use of opioid receptors as prognostic markers or therapeutic targets in urothelial carcinoma

Karim Chamie • 3 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer

Karim Chamie, MD, University of California Los Angeles, Los Angeles, CA, discusses the potential use of opioid receptors as prognostic markers or therapeutic targets in urothelial carcinoma, which may play a role in modulating tumor growth. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Karim Chamie

Results of N-803, an IL-15RαFc superagonist, with BCG in BCG-unresponsive CIS and NMIBC
1:02
Results of N-803, an IL-15RαFc superagonist, with BCG in BCG-unresponsive CIS and NMIBC
Karim Chamie • 3 Jun 2022
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals